ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Ankur Bahl, Komal Singh, Pragati Choudhary, A. K. Anand, Amal Roy Chaoudhoory, Harit Chaturvedi, Biswajyoti Hazarika, Dilip Pawar
Background: The prognosis of patients with Epidermal Growth Factor Receptor (EGFR) overexpression in inoperable Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN) remains poor. Nimotuzumab is an Anti EGFR humanized monoclonal antibody approve…
Yaa Achampong, Fani Kokka, Konstantinos Doufekas, Adeola Olaitan
Cervical cancer is the fourth most common cancer in women and is responsible for 275,000 deaths worldwide each year. The burden of this disease lies in the developing world. However it is arguably the most preventable cancer. The Human Papilloma Virus (HPV) i…
Taehun Kim, Hak Sun Chung, Wan-Hyeong Cho, Dae-Geun Jeon, So Hak Chung
Background: Unlike two known peak age groups (10 - 14 and older than 65 years of age), there was relatively scant attention in osteosarcoma patients between them, and previous reports had analyzed other than Asians. Therefore we conducted this study with Kore…
Anwar Tawfik Amin, Khalid M. Rezk, Haisam Atta
Background : Lateral neck dissection is risky and should be performed only as a therapeutic intervention for known disease. Aim of the Study : This study aims at finding predictors which help in selecting patients who have high risk of ly mph node metastasis.…
Ayaka Sato, Masahiko Tanabe, Yumi Tsuboi, Masako Ikemura, Keiichiro Tada, Yasuyuki Seto, Yoshinori Murakami
Objectives: Circulating tumor DNA (ctDNA) is shown to provide the real-time genomic information of metastatic breast cancer. This study elucidates the clinico-pathological significance of ctDNA in early-stage breast cancer using the PIK 3 CA mutation as an in…
Sulav Sapkota, Radheshyam Naik
Aims: To audit the use and outcomes of using PICC lines in hemato-oncological patients. Objectives : To study the demographics of patients : study ing the use of PICC line in hemato-oncological patients ; study ing the rate of complications in PICC line ; stu…
John Kucharczyk, Caitlin Sullivan, Jonathan Lu, Andrew Kolomensky, Edward Peters, Marc R. Matrana
Background: Immune checkpoint inhibitors produce prolonged responses in select non-small cell lung cancer (NSCLC) patients, however the identification of patients most likely to benefit is difficult. Pretreatment derived neutrophil-to-lymphocyte ratio (dNLR)…
Nurhan Onal Kalkan, Ayşe Oter Almalı, Azer Gokmen, Erkan Dogan
Tumour Lysis Syndrome (TLS) is an important oncological emergency case which is often found together with haematological malignities and, much less often, with solid tumours. While TLS seen in solid tumour cases usually develops following a cytotoxic chemothe…
Ajay B. Patel, Katherine S. Tzou, Michael G. Heckman, Colleen S. Thomas, Richard J. Lee, Nitesh Paryani, Thomas M. Pisansky, Jennifer L. Peterson, Robert C. Miller, Stephen J. Ko, Laura A. Vallow, Steven J. Buskirk
Background : We aim to estimate prostate-specific antigen (PSA) half-life after salvage radiation therapy (SRT) in patients with detectable PSA after radical prostatectomy (RP). Methods : A total of 272 patients treated with salvage radiotherapy between July…
Ajaykumar B. Patel, Katherine S. Tzou, Megan Single, Laeticia Hollant, Bridget Smart, Katherine Gaines, Courtney E. Sherman, Jennifer L. Peterson, Stephen J. Ko, Laura A. Vallow, Robert C. Miller, Steven J. Buskirk
Background : Radiation therapy prophylaxis for heterotopic ossification is well-established for the hip, either pre or post-operatively. There is limited data for this treatment in non-hip sites. We report our institution’s experience. Methods : From October…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).